We leverage our functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need and identify novel clinical positioning strategies for existing molecules.
Strategic partnerships validate Tavros’ platform and expand its potential to improve patient outcomes, minimize side effects and quicken drug development with defined patient subsets.
Tavros’ cutting-edge synthetic vulnerability platform is a breakthrough in one of the most promising areas of genetically targeted cancer treatment.
